JP2013533273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533273A5 JP2013533273A5 JP2013520856A JP2013520856A JP2013533273A5 JP 2013533273 A5 JP2013533273 A5 JP 2013533273A5 JP 2013520856 A JP2013520856 A JP 2013520856A JP 2013520856 A JP2013520856 A JP 2013520856A JP 2013533273 A5 JP2013533273 A5 JP 2013533273A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- isolated
- peptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 6
- 230000024203 complement activation Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000021736 acetylation Effects 0.000 claims 2
- 238000006640 acetylation reaction Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 101710094648 Coat protein Proteins 0.000 claims 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 241001479210 Human astrovirus Species 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 101710083689 Probable capsid protein Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000004154 complement system Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36620410P | 2010-07-21 | 2010-07-21 | |
| US61/366,204 | 2010-07-21 | ||
| PCT/US2011/044791 WO2012012600A2 (en) | 2010-07-21 | 2011-07-21 | Peptide compounds to regulate the complement system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533273A JP2013533273A (ja) | 2013-08-22 |
| JP2013533273A5 true JP2013533273A5 (enExample) | 2014-09-04 |
| JP6033774B2 JP6033774B2 (ja) | 2016-11-30 |
Family
ID=45497454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520856A Active JP6033774B2 (ja) | 2010-07-21 | 2011-07-21 | 補体系を調節するためのペプチド化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (11) | US8906845B2 (enExample) |
| EP (3) | EP2606058B1 (enExample) |
| JP (1) | JP6033774B2 (enExample) |
| CA (2) | CA3020580A1 (enExample) |
| ES (2) | ES2626182T3 (enExample) |
| PL (2) | PL3178841T3 (enExample) |
| WO (1) | WO2012012600A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10005818B2 (en) | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| CA3020580A1 (en) | 2010-07-21 | 2012-01-26 | Realta Holdings, Llc | Peptide compounds to regulate the complement system |
| ES3044832T3 (en) | 2011-06-22 | 2025-11-27 | Apellis Pharmaceuticals Inc | Methods of treating chronic disorders with complement inhibitors |
| US20150104445A1 (en) * | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
| PL3313865T3 (pl) * | 2015-06-26 | 2021-10-25 | Realta Holdings, Llc | Syntetyczne związki peptydowe i sposoby zastosowania |
| US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| CN106646992B (zh) * | 2016-12-07 | 2018-06-15 | 深圳市华星光电技术有限公司 | 一种彩膜基板、液晶面板、液晶显示装置及其制备方法 |
| CN108210503A (zh) * | 2016-12-10 | 2018-06-29 | 高尚先 | 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途 |
| TWI881481B (zh) * | 2017-08-15 | 2025-04-21 | 美商歐米諾斯公司 | 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法 |
| KR20220104268A (ko) | 2018-01-09 | 2022-07-26 | 레알타 홀딩스, 엘엘씨 | 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제 |
| KR20230078733A (ko) * | 2020-09-30 | 2023-06-02 | 리얼타 라이프 사이언시즈, 인크. | 펩티드 및 사용 방법 |
| MX2023005135A (es) * | 2020-11-02 | 2023-05-26 | Realta Life Sciences Inc | Peptidos y metodos de uso. |
| CA3194442A1 (en) * | 2020-11-02 | 2022-05-05 | Neel K. Krishna | Peptides and methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625049A (en) | 1993-05-12 | 1997-04-29 | Us Health | Nucleic acids encoding human astrovirus serotype 2 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| AU2729400A (en) | 1999-01-19 | 2000-08-07 | James Daly | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease |
| US6696562B1 (en) | 2000-07-10 | 2004-02-24 | The United States Of America As Represented By The Secretary Of Agriculture | Avian astrovirus |
| KR101132287B1 (ko) | 2003-09-05 | 2012-04-05 | 도레이 도넨 기노마쿠 고도가이샤 | 열가소성 수지 미다공막의 제조 방법 |
| WO2005023296A1 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of rheumatic diseases |
| WO2005023195A2 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7381524B2 (en) * | 2003-10-10 | 2008-06-03 | Wisconsin Alumni Research Foundation | Method to detect antibodies specific for type-2 turkey astrovirus |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2655371C (en) | 2006-06-15 | 2017-06-20 | Eastern Virginia Medical School | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| AU2008239595A1 (en) | 2007-04-11 | 2008-10-23 | Pestka Biomedical Laboratories, Inc. | Interferons of Rhesus and Cynomolgus origin and uses thereof |
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| CA3020580A1 (en) | 2010-07-21 | 2012-01-26 | Realta Holdings, Llc | Peptide compounds to regulate the complement system |
| CA2867611A1 (en) | 2012-03-16 | 2013-09-19 | Belrose Pharma, Inc. | Polymeric conjugates of c1-inhibitors |
-
2011
- 2011-07-21 CA CA3020580A patent/CA3020580A1/en not_active Abandoned
- 2011-07-21 EP EP11810386.0A patent/EP2606058B1/en active Active
- 2011-07-21 WO PCT/US2011/044791 patent/WO2012012600A2/en not_active Ceased
- 2011-07-21 PL PL17153032T patent/PL3178841T3/pl unknown
- 2011-07-21 CA CA2804998A patent/CA2804998C/en active Active
- 2011-07-21 US US13/809,371 patent/US8906845B2/en active Active
- 2011-07-21 EP EP18184643.7A patent/EP3453717A1/en not_active Ceased
- 2011-07-21 PL PL11810386T patent/PL2606058T3/pl unknown
- 2011-07-21 JP JP2013520856A patent/JP6033774B2/ja active Active
- 2011-07-21 EP EP17153032.2A patent/EP3178841B1/en active Active
- 2011-07-21 ES ES11810386.0T patent/ES2626182T3/es active Active
- 2011-07-21 ES ES17153032.2T patent/ES2688589T3/es active Active
-
2014
- 2014-11-07 US US14/536,073 patent/US9422337B2/en active Active
-
2016
- 2016-07-06 US US15/203,469 patent/US9914753B2/en active Active
-
2018
- 2018-03-09 US US15/917,137 patent/US10414799B2/en active Active
-
2019
- 2019-08-07 US US16/534,200 patent/US10844093B2/en active Active
-
2020
- 2020-10-20 US US17/075,188 patent/US20210047371A1/en not_active Abandoned
-
2021
- 2021-06-03 US US17/337,950 patent/US20210292366A1/en not_active Abandoned
-
2022
- 2022-01-12 US US17/574,098 patent/US20220127306A1/en not_active Abandoned
- 2022-08-19 US US17/821,032 patent/US20230151058A1/en not_active Abandoned
-
2024
- 2024-05-07 US US18/657,556 patent/US20240309047A1/en active Pending
- 2024-12-30 US US19/004,592 patent/US20250129124A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533273A5 (enExample) | ||
| JP2012176978A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2020023567A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| JP2016525095A5 (ja) | 環状ポリペプチド | |
| JP2015532307A5 (enExample) | ||
| JP2014529399A5 (enExample) | ||
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| JPWO2019156137A5 (enExample) | ||
| JP2014513952A5 (enExample) | ||
| JP2012524112A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2014513941A5 (enExample) | ||
| JP2019513752A5 (enExample) | ||
| JP2017531613A5 (enExample) | ||
| JP2014050390A5 (enExample) | ||
| WO2011052888A3 (ko) | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 | |
| TW201629085A (zh) | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 | |
| ZA202201828B (en) | Therapeutic fusion proteins | |
| JP2009520758A5 (enExample) | ||
| JP2020524689A5 (enExample) | ||
| CN117157049A (zh) | Atp合酶抑制剂-化妆品和治疗用途 | |
| JP2011528334A5 (enExample) |